Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRND drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRND ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PRND Products |
| Gene Delivery | PRND Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PRND Products |
| Benchmark Ab | Anti-PRND Recombinant Antibody Recombinant positive control for validation. |
View PRND Products |
| Validator | PRND siRNA Set For knockdown verification. |
View PRND Products |
| Related Target A | PRNP Prion protein paralog; critical for counter-screening to prevent off-target neurotoxicity. |
View PRNP Products |
| Related Target B | LRP1 Low-density lipoprotein receptor-related protein 1; acts as a functional partner/receptor in Doppel-mediated signaling. |
View LRP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity risk with PRNP (Prion Protein) | Human PRND and PRNP recombinant proteins strictly verified by mass spectrometry for counter-screening. |
| Native glycosylation dependency | HEK293 mammalian expression system guarantees correct N-glycosylation at Asn-99 and Asn-111. |
| Lack of Controls | Sequence-verified benchmark antibodies included as positive controls for assay baseline calibration. |
| False Positives in Cell Assays | Validated target-specific siRNA pool included for gene knockdown specificity checks. |
Live PRND R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PRND (Prion-like protein Doppel) is an emerging frontier in oncology. Normally restricted to testis tissue in healthy adults, PRND is highly upregulated in various highly aggressive malignancies, including glioblastoma multiforme (GBM), astrocytomas, osteosarcomas, and gastric cancers. Because of its restricted normal tissue expression and high tumor specificity, PRND represents an ideal target for tumor-specific therapies.
"The race for PRND therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T therapies. As first-generation targeted therapies enter preclinical validation, the next wave of R&D is targeting the specific blocking of PRND-mediated migration and chemoresistance pathways."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Academic Institutes, Biotech Startups | Glioblastoma (GBM), Solid Tumors | Internalization Assay (Need high-purity HEK293-expressed ECD-Fc for binding and internalization kinetics) |
| Monoclonal Antibody (mAb) | Oncology Research Consortia | Astrocytoma, Osteosarcoma | Selectivity Screening (Need PRND vs. PRNP counter-screening panel to avoid off-target central nervous system binding) |
| CAR-T / Cell Therapy | Translational Immunology Labs | Refractory Brain Tumors | Cell-based Activation (Need Lentivirus for stable PRND-overexpressing target cell line construction) |